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Abstract
Background: There is a well recognized association between depression and diabetes. However, there is little empirical data
about the prevalence of depressive symptoms and anxiety among different groups of glucose metabolism in population
based samples. The aim of this study was to determine whether the prevalence of increased levels of depression and anxiety
is different between patients with type 2 diabetes and subjects with impaired glucose metabolism (IGM) and normal
glucose metabolism (NGM).
Methodology/Principal Findings: Cross-sectional data from a population-based cohort study of 2667 residents, 1261 men
and 1406 women aged 40–65 years from the Hoorn region, the Netherlands. Depressive symptoms and anxiety were
measured using the Centre for Epidemiologic Studies Depression Scale (CES-D, score $16) and the Hospital Anxiety and
Depression Scale – Anxiety Subscale (HADS-A, score $8), respectively. Glucose metabolism status was determined by oral
glucose tolerance test. In the total study population the prevalence of depressive symptoms and anxiety for the NGM, IGM
and type 2 diabetes were 12.5, 12.2 and 21.0% (P = 0.004) and 15.0, 15.3 and 19.9% (p= 0.216), respectively. In men, the
prevalence of depressive symptoms was 7.7, 9.5 and 19.6% (p,0.001), and in women 16.4, 15.8 and 22.6 (p = 0.318), for
participants with NGM, IGM and type 2 diabetes, respectively. Anxiety was not associated with glucose metabolism when
stratified for sex. Intergroup differences (NGM vs. IGM and IGM vs. type 2 diabetes) revealed that higher prevalences of
depressive symptoms are mainly manifested in participants with type 2 diabetes, and not in participants with IGM.
Conclusions: Depressive symptoms, but not anxiety are associated with glucose metabolism. This association is mainly
determined by a higher prevalence of depressive symptoms in participants with type 2 diabetes and not in participants with IGM.
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Introduction
There is a well recognized association between depression and
diabetes. Evidence suggests that the relationship between these
conditions is bi-directional [1]. Yet, recently it was concluded that
there is a strong and robust association between depression and
the incidence of type 2 diabetes, but only a weak relation between
diabetes and the risk of depression [2]. The underlying mediating
factors and mechanisms of these relationships remain to be
elucidated.
It is well-known that patients with depression and diabetes,
compared with patients with diabetes alone, have been linked with
poor self-care and adherence to medical treatment [3], poorer
glycemic control [4], more diabetes complications [5], and
increased health-care use and costs [6]. Moreover, depression in
diabetes patients is associated with a higher risk of morbidity and
all cause mortality [7].
Only a few studies have addressed the prevalence of depressive
symptoms among different groups of glucose metabolism,
especially in persons with impaired glucose metabolism, or pre-
diabetes, with conflicting findings. To our knowledge Knol et al
[8] were the first reporting that in contrast to diagnosed type 2
diabetes, impaired fasting glucose was not associated with
depressive symptoms. We previously observed a gender difference,
where depressive symptoms were found to be more common in
women with impaired glucose metabolism, but not in men [9].
Other studies have shown evidence that psychological distress
increased the risk of pre-diabetes in young Swedish subjects [10],
no association between depressive symptoms and unrecognized
glucose intolerance in the United States adults [11], and a gender-
specific association in elderly men but not women living in the
United Kingdom [12]. No association was found between fasting
glucose and depression among middle-aged men [13]. Recently
Aujla et al [14] concluded that depression was not significantly
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more prevalent in people with type 2 diabetes and impaired
glucose metabolism in a multi-ethnic population. Other important
variations such as study design, type of population studied,
depression measures used, and definition of glucose status used
have led to these discrepancies. We suggested that previous
findings needed to be enlightened to further disentangle these
associations, with additional attention to the role of anxiety. So far
there has been less focus on anxiety in patients with diabetes. Yet,
there is evidence suggesting that anxiety may play a role in the
onset of type 2 diabetes [15].
Thus, the current study expands on this prior work by
investigating whether the prevalence of increased levels of
depression and anxiety is different between patients with type 2
diabetes and subjects with impaired glucose metabolism (IGM)
and normal glucose metabolism (NGM). For this purpose we used
cross sectional data from The New Hoorn Study, a large
population based-cohort study.
Methods
Participants
The study has been conducted according to the principles
expressed in the Declaration of Helsinki. All participants provided
written informed consent of their willingness to be involved. The
study was approved by the Medical Ethics Committee of the VU
University Medical Center Amsterdam.
From July 2006 until November 2007, a population-based study
on glucose tolerance was performed in the city of Hoorn, the
Netherlands (The New Hoorn Study). The New Hoorn Study has
been described in detail previously [16]. In short, a random
sample of 6180 men and women aged 40–65 years was drawn
from the municipal population registry of Hoorn. Participants
were invited to visit the Diabetes Research Center in Hoorn. Of
this sample, 2807 people agreed to participate (45.4%). Of these,
12 participants were excluded because of missing questionnaire
data, 76 participants were excluded because they had .4 items
missing on the CES-D or .1 item on the HADS-A, and another
52 participants were excluded because of missing glucose tolerance
status. The remaining 2667 participants constituted the sample for
the current study. The final response rate is 2667/6180 (43%).
Depressive symptoms
Depressive symptoms were measured using the validated Dutch
version of the 20-item Centre for Epidemiologic Studies
Depression Scale (CES-D) [17]. The CES-D measures the
frequency of depressive symptoms over the past 7 days. The
CES-D consists of 20 items and the total score can range from 0–
60. The generally used cut-off score of 16 and above was used to
identify respondents with clinically significant levels of depressive
symptoms. In participants with #4 items missing, scores were
imputed by person mean score.
Anxiety
Anxiety was measured using the Dutch version of the validated
Hospital Anxiety and Depression Scale – Anxiety Subscale
(HADS-A) [18]. The HADS-A is a scale originally developed to
indicate the possible presence of anxiety in the setting of a medical
outpatient clinic. Nowadays it is also used to indicate the presence
of anxiety in general medical patients [19]. The HADS-A consists
of 7 items and the total score can range from 0 to 21. The
generally used cut-off score of 8 and above was used to identify
respondents with the possible presence of anxiety [20]. In
participants with 1 item missing, the score was imputed by person
mean score.
Socio-demographic and clinical outcomes
Data were collected during the medical examination that was
carried out at the Diabetes Research Centre in Hoorn.
Information about age, sex, smoking, family history of diabetes
and education was assessed by means of a questionnaire. Smoking
status was defined into current smokers, past-smokers and never-
smokers. Education was classified into low, middle and high
educational level.
Fasting whole blood glucose from a capillary vein in the finger was
determined on the spot using a HemoCue Beta-glucose analyzer
(HemoCue). In 2641 of the 2667 participants, who had a fasting
whole blood glucose level below 10 mmol/l, a standard 75-g oral
glucose tolerance test (OGTT) was performed. Glucose was
measured in venous plasma by the glucose-oxidase method
(Glucoquant/hexokinase/G6P-DH; Boehringer-Mannheim, Man-
nheim, Germany). Glucose metabolism status was defined according
to the World Health Organization 2006 criteria [21].; people with
normal glucose metabolism (NGM), with impaired glucose metab-
olisms (IGM) and with type 2 diabetes NGM was defined as fasting
plasma glucose (FPG),6.1 mmol/l and 2 hr plasma glucose (2hrPG)
,7.8 mmol/l. IGM was defined as FPG 6.1–6.9 mmol/l or 2 hr PG
7.8–11.0 mmol/l. Type 2 diabetes was defined as FPG$7.0 mmol/l
or 2hrPG $11.1 mmol/l. HbA1c was assessed using a DCCT
standardized reversed-phase cation exchange chromatography (HA
8160 analyzer, Menarini, Florence, Italy) Triglycerides, HDL-
cholesterol and total cholesterol were determined from fasting plasma
samples by enzymatic techniques (Boehringer-Mannheim, Man-
nheim, Germany).
The waist circumference was measured between the lower rib
margin and the spina iliaca anterior superior. Blood pressure was
measured 3 times on the right arm after a 10 minute rest period,
using a Colin Press BP 8800p Non-Invasive Blood Pressure
Monitor (Colin Medical Technology Coorporation, USA). Final
blood pressure was calculated as the mean of the last 2
measurements. Participants were considered to be hypertensive if
their systolic pressure was .140 and/or if the diastolic pressure
was .90 and/or if they were taking antihypertensive medication.
Statistical analysis
Descriptive data are presented for the three groups of glucose
metabolism status, i.e., NGM, IGM and type 2 diabetes.
Differences in study sample characteristics for the three groups
of glucose metabolism status were examined using analysis of
variance (ANOVA) for continue variables and x2-tests for
dichotomous and categorical variables. Differences in both CES-
D (score $16) and HADS-A (score$8) prevalences and mean
depressive symptoms and anxiety scores by glucose metabolism
were calculated for the total sample and for men and women
separately, using x2-tests and ANOVA’s respectively. Additional
intergroup analyses were performed to test differences in
prevalence and mean scores of depressive symptoms and anxiety
comparing NGM vs. IGM and IGM vs. type 2 diabetes in the total
sample and stratified by sex.
Next, logistic regression analyses were carried out to contrast
the data on depressive symptoms (CES-D score $16) and anxiety
(score$8), comparing subjects with IGM or type 2 diabetes with
NGM subjects. In analyses pertaining to depressive symptoms and
anxiety, unadjusted and adjusted odds ratios with 95% confidence
intervals were obtained separately for men and women. We tested
whether adjustment for demographic variables (age, education and
family history of diabetes) and cardiovascular risk factors
(triglycerides, HDL cholesterol, total cholesterol, waist circumfer-
ence, hypertension and smoking), changed the association of
glucose status with depression and anxiety.
Depression, Anxiety, Glucose
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To further analyse the association of depression with type 2
diabetes subjects and IGM, logistic regression was performed with
depression as the outcome, and type 2 diabetes and IGM as
predictor variables. The odds ratios and 95% confidence intervals
of the unadjusted models (type 2 diabetes vs. NGM and IGM vs.
NGM) and adjusted models (age, education, family history of
diabetes, triglycerides, HDL cholesterol, total cholesterol, waist
circumference, hypertension and smoking) were calculated.
Pearson’s correlations were applied to determine the association
between continuous CES-D and HADS-A scores. All analyses
were performed using SPSS (version 15.0). For all statistical
testing, we used two-sided hypothesis testing. The p-value for
statistical significance was set at #0.05.
Results
Study population
Descriptive statistics of the total study population are presented
in table 1. The total study sample consisted of 2667 participants,
1261 men (47.3%) and 1406 women, with a mean age of 53.4
years (SD66.7). Of those 832 participants were aged 40 to 49
(31.2%), 1242 participants were aged 50 to 59 (46.6%) and 593
participants were aged 60 to 66 (22.2%).
Characteristics of the participants by glucose metabolism status
are presented in table 2. NGM was apparent in 2061 (77.3%)
participants, 425 (15.9%) had IGM and 181 (6.8%) type 2
diabetes. Age, fasting plasma glucose, 2 hour plasma glucose,
HbA1c, triglycerides, HDL-cholesterol, total cholesterol, waist
circumference, hypertension and smoking were all significantly
associated with glucose metabolism status. Depressive symptoms and anxiety in the total study
population
The prevalence (% CES-D score $16 and HADS-A score $8)
and mean scores of depressive symptoms and anxiety by glucose
metabolism status for the total study population and stratified by
sex are presented in Table 3. In the total population 229 out of
2667 (8.6%) subjects suffered from both anxiety and depression
(158 female (11%) and 71 male (5.6%)). The prevalence of
depressive symptoms for participant with NGM, IGM and type 2
diabetes was 12.5, 12.2 and 21.0% (P,0.05), respectively. Higher
mean depression scores were significantly associated with worse
metabolic status (P,0.01). Regarding anxiety, both the preva-
lences (% HADS-A score $8; NGM: 15.0, IGM: 15.3 and type 2
diabetes: 19.9%; P= 0.216) and mean scores (NGM: 4.263.5,
IGM: 3.963.6 and type 2 diabetes: 4.463.9; P= 0.196) for the
three glucose metabolism groups showed a similar trend as
depressive symptoms, but were not significant. CES-D was
associated with HADS-A scores (r = 0.69).
To further analyse the influence of possible confounders on the
association of depression with type 2 diabetes subjects and IGM,
logistic regression was performed with depression as the outcome,
and type 2 diabetes and IGM as predictor variables (Table 4).
When comparing DM2 with IGM the unadjusted odds ratio 1.86
(CI 95% 1.27–2.72) slightly dropped to 1.77 (CI 95% 1.13–2.78)
after full adjustment of age, sex, education, family history of
diabetes, triglycerides, HDL cholesterol, total cholesterol, hyper-
tension, smoking and waist circumference.
Depressive symptoms and anxiety by sex
The prevalence and mean scores of both depressive symptoms
and anxiety differ by sex (data not shown). In men, the prevalences
of depressive symptoms in the groups with NGM, IGM and type 2
diabetes were 7.7, 9.5 and 19.6% (P,0.001), respectively. Mean
depressive symptoms scores for NGM (6.166.6), IGM (6.166.7)
Table 1. Descriptive statistics of the total study population.
Male (N (%)) 1261 (47.3)
Low education (N (%)) 673 (25.7)
Current smoking (N (%)) 566 (21.4)
Family history of diabetes (N (%)) 734 (27.7)
Glucose metabolism status (N (%))
Type 2 diabetes 181 (6.8)
Impaired glucose metabolism 425 (15.9)
Normal glucose metabolism 2061 (77.3)
Age (years) N = 2667 53.466.7
Fasting Plasma glucose (mmol/l) N = 2766 5.661.0
2-hour postload plasma glucose N=2641 5.962.4
HbA1c (%) N = 2663 5.560.5
Triglycerides (mmol/l) N = 2664 1.561.1
HDL cholesterol (mmol/l) N = 2662 1.560.4
Total cholesterol mmol/l) N = 2664 5.561.0
Waist circumference (cm) N = 2665 89.8611.8
Hypertension (N (%)) 870 (32.7)
Depression prevalence (N (% CES-D $16) 348 (13.0)
Depression (CES-D mean 6 SD) N = 2667 7.467.8
Anxiety prevalence (N (% HADS-A $8)) 410 (15.4)
Anxiety (HADS-A mean 6 SD) N = 2667 4.263.5
Data are numbers (N), %, means 6 SD. Abbreviations: HADS-A, Hospital Anxiety
and Depression Scale – Anxiety Subscale; CES-D, Center for Epidemiologic
Studies Depression Scale; SD, standard deviation.
doi:10.1371/journal.pone.0009971.t001
Table 2. Characteristics of the study population by glucose
metabolism status.
NGM IGM DM2 P
N 2061 425 181
Male (%) 44.8 56.7 53.6 ,0.001
Age (years) 52.866.7 55.266.2 56.366.1 ,0.001
Low education (%) 24.4 30.0 30.4 0.080
Current smoking (%) 21.0 22.9 21.1 0.001
Family history of diabetes (%) 25.6 31.9 41.7 ,0.001
Fasting Plasma glucose (mmol/l) 5.360.4 6.060.5 7.862.2 ,0.001
2-hour postload plasma glucose 5.161.1 7.561.8 12.164.3 ,0.001
HbA1c (%) 5.360.3 5.660.3 6.561.3 ,0.001
Triglycerides (mmol/l) 1.360.7 1.861.1 2.462.8 ,0.001
HDL cholesterol (mmol/l) 1.660.4 1.460.4 1.360.4 ,0.001
Total cholesterol mmol/l) 5.461.0 5.661.1 5.361.3 0.023
Waist circumference (cm) 87.7610.6 95.4611.8 100.1613.9 ,0.001
Hypertension (%) 32.0 56.7 66.9 ,0.001
Data are %, means 6 SD. P = p-values based on one-way ANOVA for
continuous variables and x2-tests for categorical variables. Abbreviations: NGM,
normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2
diabetes; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; SD,
standard deviation.
doi:10.1371/journal.pone.0009971.t002
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and type 2 diabetes (8.468.8), confirmed the significant (P,0.010)
relationship between depressive symptoms and glucose metabo-
lism in men. This relationship could not be confirmed for anxiety.
In women with NGM, IGM and type 2 diabetes the prevalences
of depressive symptoms were 16.8, 15.8 and 22.6% (P= 0.318) and
the mean depressive symptoms scores were 8.3 (68.1), 8.1 (67.5)
and 10.6% (69.0) (P = 0.043), respectively. The prevalence of
anxiety (P = 0.542) and the mean anxiety scores (P = 0.689) were
again not significantly associated with glucose metabolism in
women.
Logistic regression analyses with depression (CES-D score $16)
and anxiety (score$8) by sex with IGM and type 2 diabetes
Table 4. Logistic regression with depression (CES-D$16) as the outcome, inclusive of unadjusted models and models adjusted for
confounding factors in the total population.
Odds Ratio (95% CI) P-value
Model 1(unadjusted)
IGM vs. NGM* 0.97 (0.71–1.34) 0.872
DM2 vs. NGM* 1.86 (1.27–2.72) 0.001
Model 2
IGM vs. NGM* 1.13 (0.81–1.57) 0.461
DM2 vs. NGM* 2.02 (1.35–3.04) 0.001
Middle/high vs. low education* 0.70 (0.53–0.94) 0.017
Female vs. Male* 1.91 (1.50–2.45) ,0.001
Age 0.98 (0.96–0.99) 0.007
Family history of DM2 vs. no family history of DM2* 1.10 (0.85–1.42) 0.476
Model 3
IGM vs. NGM* 1.09 (0.78–1.54) 0.643
DM2 vs. NGM* 1.77 (1.13–2.78) 0.013
Middle/high vs. low education* 0.71 (0.53–0.95) 0.022
Female vs. Male* 2.10 (1.59–2.78) ,0.001
Age 0.99 (0.97–1.00) 0.104
Family history of DM2 vs. no family history of DM2* 1.09 (0.84–1.41) 0.526
Triglycerides 1.21 (1.02–1.43) 0.027
HDL cholesterol 1.17 (0.82–1.67) 0.402
Total cholesterol 0.80 (0.70–0.92) 0.002
Hypertension vs. no hypertension* 0.59 (0.44–0.79) ,0.001
Current smoker vs. non-current smoker* 1.21 (0.92–1.60) 0.177
Waist circumference 1.01 (1.00–1.02) 0.096
Abbreviations: NGM, normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2 diabetes (WHO 2006 criteria).
*Denotes reference category.
doi:10.1371/journal.pone.0009971.t004
Table 3. Prevalence and mean scores of depressive symptoms and anxiety by glucose metabolism status for the total study
population and stratified according to sex.
Total Male Female
NGM
(N=2061)
IGM
(N=425)
DM2
(N=181) P
NGM
(N=923)
IGM
(N=241)
DM2
(N=97) P
NGM
(N=1138)
IGM
(N=184)
DM2
(N=84) P
CES-D
$16 (%) 12.5 12.2 21.0a 0.004 7.7 9.5 19.6a ,0.001 16.4 15.8 22.6 0.318
Mean6SD 7.367.5 7.067.1 9.468.9a 0.001 6.166.6 6.166.7 8.468.8a 0.007 8.368.1 8.167.5 10.669.0a 0.043
HADS-A
$8 (%) 15.0 15.3 19.9 0.216 10.2 11.6 16.5 0.155 18.9 20.1 23.8 0.524
Mean6SD 4.263.5 3.963.6 4.463.9 0.196 3.763.2 3.563.4 4.063.7 0.389 4.663.6 4.563.8 4.963.7 0.689
Data are %, means 6 SD. P = p-values based on one-way ANOVA for continuous variables and x2-tests for categorical variables. a significantly different comparing IGM
vs. DM2. Abbreviations: NGM, normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2 diabetes; SD, standard deviation; HADS-A. Hospital Anxiety
and Depression Scale – Anxiety Subscale; CES-D, Center for Epidemiologic Studies Depression Scale.
doi:10.1371/journal.pone.0009971.t003
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subjects compared with NGM subjects were performed, including
unadjusted and adjusted models (Table 5). The unadjusted odds
ratio of 2.92 (CI 95% 1.68–5.10) for depression in men decreased
2.55 CI 95% 1.34–4.86) after adjustment for age, education,
family history of diabetes, triglycerides, HDL cholesterol, total
cholesterol, hypertension, smoking and waist circumference,
though remain significant. In women, none of the odds ratios
for depression in the unadjusted and adjusted models (Model 1, 2
and 3) were significant.
Intergroup differences
Additional analyses were performed to test intergroup differ-
ences (NGM vs. IGM and IGM vs. type 2 diabetes) in prevalence
and mean scores of depressive symptoms and anxiety by glucose
metabolism status for the total sample and by sex (Table 3). We
found no differences in the prevalences of depression and mean
depressive symptoms when comparing NGM versus IGM neither
for the total population nor for men or women separately.
However, when comparing IGM versus type 2 diabetes, all
prevalences of depression and mean depressive symptoms scores
for the total sample and across sex appeared to be different, except
for the depressive symptoms prevalences among women
(P = 0.174). No differences in prevalences of anxiety and mean
anxiety scores for the total sample and by sex were found
comparing NGM vs. IGM and IGM vs. type 2 diabetes. These
results strongly suggests that the association between depressive
symptoms and glucose metabolism is mainly determined by the
higher prevalence of depressive symptoms in participants with type
2 diabetes and not in participants with IGM.
Discussion
To our knowledge, this is the first study inquiring both
depressive symptoms and anxiety among different groups of
glucose metabolism status in a large population based sample
using oral glucose tolerance test. Our results show an association
between depressive symptoms and glucose metabolism status but
not anxiety. In addition, this association seems to be mainly
determined by the higher prevalence of depressive symptoms in
participants with type 2 diabetes and not in participants with IGM.
This finding is in line with previous studies [8,10,12], although
other studies did not show an association [11]. The outcomes
partly match with previous findings of our study group [9]. We
previously concluded that depressive symptoms were more
common in women with impaired glucose metabolism. This
conclusion is not fully supported by our present study. This could
be due to differences in sample size, methodological issues and age
of the studied population. Given the large sample size of our
present study population and scoring patterns of the primary
outcomes across glucose metabolism, the total sample and sex, it is
reasonable to believe that the findings presented are valid. Our
results do not confirm the results of a study by Aujla et. al.,
concluding that depression was not significantly more prevalent in
people with type 2 diabetes and impaired glucose metabolism [14].
A possible explanation is the use of different measures in defining
depression. Where Aujla et. al., defined depression by a WHO-5
wellbeing score #13, we used a depression specific instrument
(CES-D), using the well documented cut-score of $16.
Based on the work of Engum [15], and the marked degree of
correlation between anxiety and depressive symptoms in our
sample, we expected to find a relation between anxiety and glucose
metabolism status. However, our data did not show such a
relationship. Moreover, we found no association between anxiety
and glucose metabolism in neither the total sample or in men and
women separately. These findings are robust and appeared to be
valid for both the prevalence (dichotomous) and mean (continuous)
anxiety scores. Yet, the outcomes need to be interpreted with
caution since anxiety scores show virtually the same distributions
among the three glucose groups as depression scores, though not
significant. The fact that we did not find such a relationship is hard
Table 5. Odds ratios for depression (CES-D score $16) and anxiety (HADS-A $16) by sex with impaired glucose metabolism or
type 2 diabetes subjects compared with normal glucose metabolism subjects.
n % Unadjusted OR (95 CI)* Model 1 OR (95 CI)1 Model 2 OR (95 CI)" Model 3 OR (95 CI){
Depression
Men NGM 923 7.7 referent referent referent referent
IGM 241 9.5 1.27 (0.77–2.07) 1.26 (0.76–2.09) 1.13 (0.67–1.90) 1.14 (0.67–1.94)
DM2 97 19.6 2.92 (1.68–5.10) 3.16 (1.78–5.62) 2.55 (1.38–4.73) 2.55 (1.34–4.86)
Women NGM 1138 16.4 referent referent referent referent
IGM 184 15.8 0.95 (0.62–1.46) 1.07 (0.69–1.66) 1.08 (0.66–1.63) 1.05 (0.67–1.67)
DM2 84 22.6 1.49 (0.78–2.54) 1.39 (0.78–2.49) 1.30 (0.70–2.40) 1.37 (0.71–2.62)
Anxiety
Men NGM 923 10.2 referent referent referent referent
IGM 241 11.6 1.16 (0.74–1.81) 1.11 (0.70–1.78) 1.08 (0.67–1.75) 1.07 (0.65–1.76)
DM2 97 16.5 1.74 (0.98–3.10) 1.91 (1.06–3.47) 1.73 (0.92–3.26) 1.58 (0.82–3.06)
Women NGM 1138 18.9 referent referent referent referent
IGM 184 20.1 1.08 (0.73–1.60) 1.16 (0.78–1.74) 1.12 (0.74–1.70) 1.14 (0.74–1.75)
DM2 84 23.8 1.34 (0.80–2.27) 1.33 (0.76–2.31) 1.24 (0.69–2.23) 1.36 (0.74–2.51)
Abbreviations: NGM, normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2 diabetes (WHO 2006 criteria).
*The unadjusted odds ratios.
1Model 1: Adjusted for age, education and family history of diabetes.
"Model 2: Adjusted for Model 1 and triglycerides, HDL cholesterol, and total cholesterol.
{Model 3. Adjusted for Model 2 and, hypertension, smoking and waist circumference.
doi:10.1371/journal.pone.0009971.t005
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to explain, but could be attributed to the difference in anxiety
measure at baseline (Anxiety and Depression Index) and definition
of diabetes (self-reported) by Engum. Further prospective and
experimental studies are needed to disentangle the role of
depression and anxiety (generalized anxiety, panic disorder,
phobias) in relation to glucose metabolism.
Impaired glucose metabolism is an important predictor of
developing type 2 diabetes [22] and, a bidirectional relationship
between depressive symptoms and glucose metabolism status exists
[1]. This implies that depressive symptoms would gradually rise
among the three different groups of glucose metabolism. Our
results do not support this hypothesis. We found highest levels of
depressive symptoms in subjects with type 2 diabetes and not in
NGM or IGM. This pattern was true for the total study sample as
well as for men and women separately. Inter group comparisons
confirmed these findings.
In this study highest levels of depressive symptoms in subjects
with type 2 diabetes were found. It has been suggested that the
onset of depressive symptoms comes from the stresses and strains
of the knowledge that one has type 2 diabetes [23]. However, this
is unlikely given the accumulating evidence that newly diagnosed
type 2 diabetes has no substantial short and long term
psychological impact [24].
The mechanisms that underlie the association between
depression and type 2 diabetes are unclear, though have been
described previously [9,15]. Potential mechanistic pathways
include the influence of depressive symptoms on behavioural
factors, such as sedentary lifestyles, smoking and overeating,
resulting is metabolic disturbances, which may explain the onset of
diabetes. Alternative mechanisms include, for example, deregula-
tion of the hypothalamic–pituitary–adrenal axis and the sympa-
thetic nervous system [25], sex steroid hormone levels [26], low
grade inflammation [27], or vitamin D deficiency [28]. More
research is needed with regard to factors underlying these
biological mechanisms.
The strengths of our study are that we used data from a large
population-based sample of male and female subjects. Gold-
standard assessment was used to determine glucose metabolism
status (i.e., OGTT). Next, we used the CES-D and HADS-A
which are both validated and widely used instruments including
well-documented cut-points, also applied in populations with
diabetes [29]. Finally, the outcomes are presented for the total
population and for men and women separately because of the
significant difference in primary outcomes by sex.
Some limitations of our study need to be addressed. First, the
present study has a cross-sectional design, thus we cannot infer
causality between depressive symptoms, anxiety and glucose
metabolism status. Second, we used a self-report measure (CES-
D) to measure depressive symptoms, while the psychiatric
diagnostic interview is considered the gold standard. However
this diagnostic interview is not easy to apply in large-scale
epidemiological studies. Third, the excluded participants were
more often female and more often low educated. It is possible that
the percentage of women with depressive symptoms in our study
population is under- or overestimated. However, this excluded
proportion of participants is only a small percentage of the total
population and therefore not likely to influence the outcomes.
Finally, the present study was limited to a Dutch Caucasian adult
population. It is not clear whether the relationship between
depression, anxiety and glucose is consistent across different ethnic
and age groups. Interestingly, no differences in prevalent
depression were found in a multi-ethnic population recently [14].
In conclusion, the present study shows in a large population
based sample that depressive but not anxiety is associated with
glucose metabolism status. This association is mainly determined
by a higher prevalence of depressive symptoms in participants with
type 2 diabetes and not in participants with IGM. Further well-
designed prospective research is needed: (a) to test whether
depression and or anxiety, using the psychiatric diagnostic
interview, is associated with an increased risk of developing type
2 diabetes, diagnosed according to an OGTT; (b) to disentangle
the complex causal relationships between (the onset of) type 2
diabetes, depressive symptoms and anxiety; and (c) to clarify
pathophysiological mechanisms underlying these relationships.
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